CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Galenea Corp. and CHDI Foundation, Inc. announce the extension and expansion of their collaboration to further characterize the synaptic dysfunction apparent in Huntington’s disease (HD) utilizing Galenea’s proprietary synaptic transmission drug discovery platform. Galenea’s innovative platform is providing significant new insights into the disease mechanism, and the collaboration will now focus on extending these findings in order to specifically target this mechanism to discover novel therapies for HD.
